Activin and inhibin, estrogens and NFκB, play roles in ovarian tumourigenesis is there crosstalk?

Molecular and Cellular Endocrinology

Volumn 359, Issue 1-2, 2012, Pages 85-91

  Drummond, Ann E ^a   Fuller, Peter J ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Estrogen; NF B; Ovarian cancer; TGF

Indexed keywords

ACTIVIN; ESTROGEN; GLYCOGEN SYNTHASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; X LINKED INHIBITOR OF APOPTOSIS;

BINDING SITE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; GENE OVEREXPRESSION; GRANULOSA CELL; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; MOLECULAR INTERACTION; NONHUMAN; OVARY CANCER; OVARY FUNCTION; PHYLOGENOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME;

ACTIVIN RECEPTORS; ACTIVINS; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; INHIBINS; NF-KAPPA B; OVARIAN NEOPLASMS; RECEPTOR CROSS-TALK; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 84860232833     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.07.033     Document Type: Review

References (124)

1. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
2. Bardin A., Hoffmann P., Boulle N., Katsaros D., Vignon F., Pujol P., Lazennec G. Involvement of estrogen receptor beta in ovarian carcinogenesis. Cancer Res. 2004, 64:5861-5869.
3. Basseres D.S., Baldwin A.S. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006, 25:6817-6830.
4. Baud V., Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug. Discov. 2009, 8:33-40.
5. Bonome T., Levine D.A., Shih J., Randonovich M., Pise-Masison C.A., Bogomolniy F., Ozbun L., Brady J., Barrett J.C., Boyd J., Birrer M.J. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008, 68:5478-5486.
6. Brandenberger A.W., Tee M.K., Jaffe R.B. Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. J. Clin. Endocrinol. Metab. 1998, 83:1025-1028.
7. Burger H.G. Evidence for a negative feedback role of inhibin in follicle stimulating hormone regulation in women. Hum Reprod. 1993, 8(Suppl. 2):129-132.
8. Burger H.G. The endocrinology of the menopause. J. Steroid. Biochem. Mol. Biol. 1999, 69:31-35.
9. Burger H.G., Fuller P.J., Chu S., Mamers P., Drummond A., Susil B., Neva P., Robertson D.M. The inhibins and ovarian cancer. Mol. Cell. Endocrinol. 2001, 180:145-148.
10. Choi K.C., Kang S.K., Tai C.J., Auersperg N., Leung P.C. The regulation of apoptosis by activin and transforming growth factor-beta in early neoplastic and tumorigenic ovarian surface epithelium. J. Clin. Endocrinol. Metab. 2001, 86:2125-2135.
11. Choi Y.L., Kim H.S., Ahn G. Immunoexpression of inhibin alpha subunit, inhibin/activin betaA subunit and CD99 in ovarian tumors. Arch. Pathol. Lab. Med. 2000, 124:563-569.
12. Chu S., Nishi Y., Yanase T., Nawata H., Fuller P.J. Transrepression of estrogen receptor beta signaling by nuclear factor-kappab in ovarian granulosa cells. Mol. Endocrinol. 2004, 18:1919-1928.
13. Chudecka-Glaz A., Rzepka-Gorska I. Activin A levels in serum and cyst fluid in epithelial tumors of the ovary. Int. J. Gynaecol. Obstet. 2005, 89:160-162.
14. Cobellis L., Reis F.M., Luisi S., Danero S., Pirtoli L., Scambia G., Petraglia F. High concentrations of activin A in the peritoneal fluid of women with epithelial ovarian cancer. J. Soc. Gynecol. Investig. 2004, 11:203-206.
15. Coerver K.A., Woodruff T.K., Finegold M.J., Mather J., Bradley A., Matzuk M.M. Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice. Mol. Endocrinol. 1996, 10:534-543.
16. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
17. Cunat S., Hoffmann P., Pujol P. Estrogens and epithelial ovarian cancer. Gynecol. Oncol. 2004, 94:25-32.
18. De Bosscher K., Vanden Berghe W., Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev. 2003, 24:488-522.
19. Deregowski V., Delhalle S., Benoit V., Bours V., Merville M.P. Identification of cytokine-induced nuclear factor-kappaB target genes in ovarian and breast cancer cells. Biochem. Pharmacol. 2002, 64:873-881.
20. Di Simone N., Crowley W.F., Wang Q.F., Sluss P.M., Schneyer A.L. Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology 1996, 137:486-494.
21. Do T.V., Kubba L.A., Antenos M., Rademaker A.W., Sturgis C.D., Woodruff T.K. The role of activin A and Akt/GSK signaling in ovarian tumor biology. Endocrinology 2008, 149:3809-3816.
22. Duggan B.D., Wan M., Yu M.C., Roman L.D., Muderspach L.I., Delgadillo E., Li W.Z., Martin S.E., Dubeau L. Detection of ovarian cancer cells: comparison of a telomerase assay and cytologic examination. J. Natl. Cancer Inst. 1998, 90:238-242.
23. Espey L.L. Ovulation as an inflammatory reaction - a hypothesis. Biol. Reprod. 1980, 22:73-106.
24. Fan X., Gabbi C., Kim H.J., Cheng G., Andersson L.C., Warner M., Gustafsson J.A. Gonadotropin-positive pituitary tumors accompanied by ovarian tumors in aging female ERbeta-/- mice. Proc. Natl. Acad. Sci. USA 2010, 107:6453-6458.
25. Fleming J.S., Beaugié C.R., Haviv I., Chenevix-Trench G., Tan O.L. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: Revisiting old hypotheses. Mol. Cell. Endocrinol. 2006, 247(1-2):4-21. [Epub 2005 Nov 16].
26. Fujii A., Harada T., Yamauchi N., Iwabe T., Nishi Y., Yanase T., Nawata H., Terakawa N. Interleukin-8 gene and protein expression are up-regulated by interleukin-1beta in normal human ovarian cells and a granulosa tumor cell line. Fertil. Steril. 2003, 79:151-157.
27. Fujimura M., Hidaka T., Kataoka K., Yamakawa Y., Akada S., Teranishi A., Saito S. Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. Am. J. Surg. Pathol. 2001, 25:667-672.
28. Gadducci A., Cosio S., Gargini A., Genazzani A.R. Sex-steroid hormones, gonadotropin and ovarian carcinogenesis: a review of epidemiological and experimental data. Gynecol. Endocrinol. 2004, 19(4):216-228.
29. Gambacciani M., Monteleone P., Sacco A., Genazzani A.R. Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Best Pract. Res. Clin. Endocrinol. Metab. 2003, 17:139-147.
30. Gao N., Nester R.A., Sarkar M.A. 4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/Akt/FRAP pathway in OVCAR-3 and A2780-CP70 human ovarian carcinoma cells. Toxicol. Appl. Pharmacol. 2004, 196:124-135.
31. Ghosh S., May M.J., Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 1998, 16:225-260.
32. Gorospe W.C., Spangelo B.L. Interleukin-6 production by rat granulosa cells in vitro: effects of cytokines, follicle-stimulating hormone, and cyclic 3', 5'-adenosine monophosphate. Biol. Reprod. 1993, 48:538-543.
33. Gubbels J.A., Claussen N., Kapur A.K., Connor J.P., Patankar M.S. The detection, treatment, and biology of epithelial ovarian cancer. J. Ovarian. Res. 2010, 29:3-8.
34. Guo R.X., Qiao Y.H., Zhou Y., Li L.X., Shi H.R., Chen K.S. Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol. Int. 2008, 58:749-756.
35. Gurusinghe C.J., Healy D.L., Jobling T., Mamers P., Burger H.G. Inhibin and activin are demonstrable by immunohistochemistry in ovarian tumor tissue. Gynecol. Oncol. 1995, 57:27-32.
36. Hacker, H., Karin, M., 2006. Regulation and function of IKK and IKK-related kinases, Sci. STKE, 2006, re13.
37. Halon, A., Materna, V., Drag-Zalesinska, M., Nowak-Markwitz, E., Gansukh, T., Donizy, P., Spaczynski, M., Zabel, M., Dietel, M., Lage, H., Surowiak, P., 2011. Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol. Oncol. Res.
38. Hanna L., Adams M. Prevention of ovarian cancer. Best. Pract. Res. Clin. Obstet. Gynaecol. 2006, 20:339-362.
39. Hatch K.D., Beecham J.B., Blessing J.A., Creasman W.T. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991, 68:269-271.
40. Healy D.L., Burger H.G., Mamers P., Jobling T., Bangah M., Quinn M., Grant P., Day A.J., Rome R., Campbell J.J. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N. Engl. J. Med. 1993, 329:1539-1542.
41. Hernandez L., Hsu S.C., Davidson B., Birrer M.J., Kohn E.C., Annunziata C.M. Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res. 2010, 70:4005-4014.
42. Hewitt S.C., Deroo B.J., Korach K.S. Signal transduction. A new mediator for an old hormone?. Science 2005, 307:1572-1573.
43. Hillier S.G., Anderson R.A., Williams A.R., Tetsuka M. Expression of oestrogen receptor alpha and beta in cultured human ovarian surface epithelial cells. Mol. Hum. Reprod. 1998, 4:811-815.
44. Hillier S.G., Yong E.L., Illingworth P.J., Baird D.T., Schwall R.H., Mason A.J. Effect of recombinant inhibin on androgen synthesis in cultured human thecal cells. Mol. Cell. Endocrinol. 1991, 75:R1-R6.
45. Hinds L., Price J. Menopause, hormone replacement and gynaecological cancers. Menopause Int. 2010, 16:89-93.
46. Hunzicker-Dunn M., Maizels E.T. FSH signaling pathways in immature granulosa cells that regulate target gene expression: branching out from protein kinase A. Cell Signal. 2006, 18:1351-1359.
47. Ito K., Utsunomiya H., Niikura H., Yaegashi N., Sasano H. Inhibition of estrogen actions in human gynecological malignancies: New aspects of endocrine therapy for endometrial cancer and ovarian cancer. Mol. Cell Endocrinol. 2010, 340(2):161-167.
48. Jobling T., Mamers P., Healy D.L., MacLachlan V., Burger H.G., Quinn M., Rome R., Day A.J. A prospective study of inhibin in granulosa cell tumors of the ovary. Gynecol. Oncol. 1994, 55:285-289.
49. Kalaitzidis D., Gilmore T.D. Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol. Metab. 2005, 16:46-52.
50. Karin M. NF-kappaB and cancer: mechanisms and targets. Mol. Carcinog. 2006, 45:355-361.
51. Karin M., Cao Y., Greten F.R., Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2002, 2:301-310.
52. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5:749-759.
53. Karst A.M., Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J. Oncol. 2010, 2010:932371.
54. Kimura A., Ohmichi M., Kawagoe J., Kyo S., Mabuchi S., Takahashi T., Ohshima C., Arimoto-Ishida E., Nishio Y., Inoue M., Kurachi H., Tasaka K., Murata Y. Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines. Oncogene 2004, 23:4505-4515.
55. Kleinberg L., Davidson B. Cell survival and apoptosis-related molecules in cancer cells in effusions: a comprehensive review. Diagn. Cytopathol. 2009, 37:613-624.
56. Knight P.G., Glister C. TGF-beta superfamily members and ovarian follicle development. Reproduction 2006, 132:191-206.
57. Kommoss F., Oliva E., Bhan A.K., Young R.H., Scully R.E. Inhibin expression in ovarian tumors and tumor-like lesions: an immunohistochemical study. Mod. Pathol. 1998, 11:656-664.
58. Kurebayashi S., Miyashita Y., Hirose T., Kasayama S., Akira S., Kishimoto T. Characterization of mechanisms of interleukin-6 gene repression by estrogen receptor. J. Steroid. Biochem. Mol. Biol. 1997, 60:11-17.
59. Kurman R.J., Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol. 2010, 34:433-443.
60. Landen C.N., Birrer M.J., Sood A.K. Early events in the pathogenesis of epithelial ovarian cancer. J. Clin. Oncol. 2008, 26:995-1005.
61. Lappohn R.E., Burger H.G., Bouma J., Bangah M., Krans M., de Bruijn H.W. Inhibin as a marker for granulosa-cell tumors. N. Engl. J. Med. 1989, 321:790-793.
62. Lee Y., Miron A., Drapkin R., Nucci M.R., Medeiros F., Saleemuddin A., Garber J., Birch C., Mou H., Gordon R.W., Cramer D.W., McKeon F.D., Crum C.P. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 2007, 211:26-35.
63. Li A.J., Baldwin R.L., Karlan B.Y. Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. Am. J. Obstet. Gynecol. 2003, 189:22-27.
64. Li Q., Graff J.M., O'Connor A.E., Loveland K.L., Matzuk M.M. SMAD3 regulates gonadal tumorigenesis. Mol. Endocrinol. 2007, 21:2472-2486.
65. Li Q., Kumar R., Underwood K., O'Connor A.E., Loveland K.L., Seehra J.S., Matzuk M.M. Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein. Mol. Hum. Reprod. 2007, 13:675-683.
66. Lindgren P.R., Cajander S., Backstrom T., Gustafsson J.A., Makela S., Olofsson J.I. Estrogen and progesterone receptors in ovarian epithelial tumors. Mol. Cell. Endocrinol. 2004, 221:97-104.
67. Lopez-Rovira T., Chalaux E., Rosa J.L., Bartrons R., Ventura F. Interaction and functional cooperation of NF-kappa B with Smads. Transcriptional regulation of the junB promoter. J. Biol. Chem. 2000, 275:28937-28946.
68. Mabuchi S., Ohmichi M., Nishio Y., Hayasaka T., Kimura A., Ohta T., Kawagoe J., Takahashi K., Yada-Hashimoto N., Seino-Noda H., Sakata M., Motoyama T., Kurachi H., Testa J.R., Tasaka K., Murata Y. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin. Cancer Res. 2004, 10:7645-7654.
69. Mabuchi S., Ohmichi M., Nishio Y., Hayasaka T., Kimura A., Ohta T., Saito M., Kawagoe J., Takahashi K., Yada-Hashimoto N., Sakata M., Motoyama T., Kurachi H., Tasaka K., Murata Y. Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J. Biol. Chem. 2004, 279:23477-23485.
70. Mabuchi Y., Yamoto M., Minami S., Umesaki N. The autocrine effect of activin A on human ovarian clear cell adenocarcinoma cells. Oncol. Rep. 2006, 16:373-379.
71. Machelon V., Nome F., Salesse R. Comparative IL-6 effects on FSH and hCG-induced functions in porcine granulosa cell cultures. Cell. Mol. Biol. (Noisy-le-grand). 1994, 40:373-380.
72. Massague J., Cheifetz S., Laiho M., Ralph D.A., Weis F.M., Zentella A. Transforming growth factor-beta. Cancer Surv. 1992, 12:81-103.
73. Matzuk M.M., Finegold M.J., Su J.G., Hsueh A.J., Bradley A. Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 1992, 360:313-319.
74. Matzuk M.M., Kumar T.R., Shou W., Coerver K.A., Lau A.L., Behringer R.R., Finegold M.J. Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development. Recent Prog. Horm. Res. 1996, 51:123-154. (discussion 155-7).
75. McLachlan R.I., Robertson D.M., de Kretser D., Burger H.G. Inhibin - a non-steroidal regulator of pituitary follicle stimulating hormone. Baillieres Clin. Endocrinol. Metab. 1987, 1:89-112.
76. Menon U., Riley S.C., Thomas J., Bose C., Dawnay A., Evans L.W., Groome N.P., Jacobs I.J. Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma. BJOG 2000, 107:1069-1074.
77. Moll F., Katsaros D., Lazennec G., Hellio N., Roger P., Giacalone P.L., Chalbos D., Maudelonde T., Rochefort H., Pujol P. Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells. Oncogene 2002, 21:1097-1107.
78. Murphy S.K. Targeting ovarian cancer-initiating cells. Anticancer Agents Med. Chem. 2010, 10:157-163.
79. Nagaraja A.K., Middlebrook B.S., Rajanahally S., Myers M., Li Q., Matzuk M.M., Pangas S.A. Defective gonadotropin-dependent ovarian folliculogenesis and granulosa cell gene expression in inhibin-deficient mice. Endocrinology 2010, 151:4994-5006.
80. Nagarajan R.P., Chen F., Li W., Vig E., Harrington M.A., Nakshatri H., Chen Y. Repression of transforming-growth-factor-beta-mediated transcription by nuclear factor kappaB. Biochem. J. 2000, 348(Pt. 3):591-596.
81. Nezhat F., Datta M.S., Hanson V., Pejovic T., Nezhat C. The relationship of endometriosis and ovarian malignancy: a review. Fertil. Steril. 2008, 90:1559-1570.
82. O'Dea E., Hoffmann A. NF-kappaB signaling. Wiley Interdiscip Rev. Syst. Biol. Med. 2009, 1:107-115.
83. O'Donnell A.J., Macleod K.G., Burns D.J., Smyth J.F., Langdon S.P. Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr. Relat. Cancer 2005, 12:851-866.
84. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol. 2007, 8:49-62.
85. Petraglia F., Luisi S., Pautier P., Sabourin J.C., Rey R., Lhomme C., Bidart J.M. Inhibin B is the major form of inhibin/activin family secreted by granulosa cell tumors. J. Clin. Endocrinol. Metab. 1998, 83:1029-1032.
86. Pujol P., Rey J.M., Nirde P., Roger P., Gastaldi M., Laffargue F., Rochefort H., Maudelonde T. Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res. 1998, 58:5367-5373.
87. Rahimi R.A., Leof E.B. TGF-beta signaling: a tale of two responses. J. Cell. Biochem. 2007, 102:593-608.
88. Rajanahally S., Agno J.E., Nalam R.L., Weinstein M.B., Loveland K.L., Matzuk M.M., Li Q. Genetic evidence that SMAD2 is not required for gonadal tumor development in inhibin-deficient mice. Reprod. Biol. Endocrinol. 2010, 8:69.
89. Ramachandran A., Marshall E.S., Love D.R., Baguley B.C., Shelling A.N. Activin is a potent growth suppressor of epithelial ovarian cancer cells. Cancer Lett. 2009, 285:157-165.
90. Rao B.R., Slotman B.J. Endocrine factors in common epithelial ovarian cancer. Endocr. Rev. 1991, 12:14-26.
91. Rauh-Hain J.A., Krivak T.C., Del Carmen M.G., Olawaiye A.B. Ovarian cancer screening and early detection in the general population. Rev. Obstet. Gynecol. 2002, 4:15-21.
92. Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., Prossnitz E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005, 307:1625-1630.
93. Ricciardelli C., Oehler M.K. Diverse molecular pathways in ovarian cancer and their clinical significance. Maturitas 2009, 62:270-275.
94. Robertson D.M., Burger H.G., Fuller P.J. Inhibin/activin and ovarian cancer. Endocr. Relat Cancer 2004, 11:35-49.
95. Robertson D.M., Cahir N., Burger H.G., Mamers P., McCloud P.I., Pettersson K., McGuckin M. Combined inhibin and CA125 assays in the detection of ovarian cancer. Clin. Chem. 1999, 45:651-658.
96. Robertson D.M., Stephenson T., Pruysers E., McCloud P., Tsigos A., Groome N., Mamers P., Burger H.G. Characterization of inhibin forms and their measurement by an inhibin alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer. J. Clin. Endocrinol. Metab. 2002, 87:816-824.
97. Rodriguez C., Calle E.E., Coates R.J., Miracle-McMahill H.L., Thun M.J., Heath C.W. Estrogen replacement therapy and fatal ovarian cancer. Am. J. Epidemiol. 1995, 141:828-835.
98. Rodriguez C., Patel A.V., Calle E.E., Jacob E.J., Thun M.J. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001, 285:1460-1465.
99. Sakumoto R., Okuda K. Possible actions of tumor necrosis factor-alpha in ovarian function. J. Reprod. Dev. 2004, 50:39-46.
100. Samanta A.K., Huang H.J., Le X.F., Mao W., Lu K.H., Bast R.C., Liao W.S. MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma. Cancer 2009, 115:3897-3908.
101. Santen R.J., Allred D.C., Ardoin S.P., Archer D.F., Boyd N., Braunstein G.D., Burger H.G., Colditz G.A., Davis S.R., Gambacciani M., Gower B.A., Henderson V.W., Jarjour W.N., Karas R.H., Kleerekoper M., Lobo R.A., Manson J.E., Marsden J., Martin K.A., Martin L., Pinkerton J.V., Rubinow D.R., Teede H., Thiboutot D.M., Utian W.H. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J. Clin. Endocrinol. Metab. 2010, 95:s1-s66.
102. Sasaki H., Hayakawa J., Terai Y., Kanemura M., Tanabe-Kimura A., Kamegai H., Seino-Noda H., Ezoe S., Matsumura I., Kanakura Y., Sakata M., Tasaka K., Ohmichi M. Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines. Oncogene 2008, 27:2737-2745.
103. Schorge J.O., Modesitt S.C., Coleman R.L., Cohn D.E., Kauff N.D., Duska L.R., Herzog T.J. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol. Oncol. 2010, 119(1):7-17. [Epub 2010 Aug 7].
104. Sethi G., Sung B., Aggarwal B.B. Nuclear factor-kappaB activation: from bench to bedside. Exp. Biol. Med. (Maywood) 2008, 233:21-31.
105. Shih Ie M., Davidson B. Pathogenesis of ovarian cancer: clues from selected overexpressed genes. Future Oncol. 2009, 5:1641-1657.
106. Shih Ie M., Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 2004, 164:1511-1518.
107. Shikone T., Matzuk M.M., Perlas E., Finegold M.J., Lewis K.A., Vale W., Bradley A., Hsueh A.J. Characterization of gonadal sex cord-stromal tumor cell lines from inhibin-alpha and p53-deficient mice: the role of activin as an autocrine growth factor. Mol. Endocrinol. 1994, 8:983-995.
108. Singh P., Oehler M.K. Hormone replacement after gynaecological cancer. Maturitas 2010, 65:190-197.
109. Smyth C.D., Gosden R.G., McNeilly A.S., Hillier S.G. Effect of inhibin immunoneutralization on steroidogenesis in rat ovarian follicles in vitro. J. Endocrinol. 1994, 140:437-443.
110. Solt L.A., May M.J. The IkappaB kinase complex: master regulator of NF-kappaB signaling. Immunol. Res. 2008, 42:3-18.
111. Son D.S., Roby K.F. Interleukin-1alpha-induced chemokines in mouse granulosa cells: impact on keratinocyte chemoattractant chemokine, a CXC subfamily. Mol. Endocrinol. 2006, 20:2999-3013.
112. Steller M.D., Shaw T.J., Vanderhyden B.C., Ethier J.F. Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. Mol Cancer Res. 2005, 3:50-61.
113. Stice J.P., Knowlton A.A. Estrogen, NFkappaB, and the heat shock response. Mol. Med. 2008, 14:517-527.
114. Syed V., Ulinski G., Mok S.C., Yiu G.K., Ho S.M. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res. 2001, 61:6768-6776.
115. Tanaka T., Toujima S., Umesaki N. Growth-inhibitory signals by activin A do not affect anticancer drug-sensitivity and acquired multi-drug-resistance in human ovarian endometrioid adenocarcinoma OVK-18 cells. Oncol Rep. 2004, 11:667-671.
116. Walker G., MacLeod K., Williams A.R., Cameron D.A., Smyth J.F., Langdon S.P. Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol. Oncol. 2007, 106:461-468.
117. Wang Y., Rippstein P.U., Tsang B.K. Role and gonadotrophic regulation of X-linked inhibitor of apoptosis protein expression during rat ovarian follicular development in vitro. Biol. Reprod. 2003, 68:610-619.
118. Welt C.K., Lambert-Messerlian G., Zheng W., Crowley W.F., Schneyer A.L. Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma. J. Clin. Endocrinol. Metab. 1997, 82:3720-3727.
119. Wimalasena J., Meehan D., Cavallo C. Human epithelial ovarian cancer cell steroid secretion and its control by gonadotropins. Gynecol. Oncol. 1991, 41:56-63.
120. Yang N., Huang J., Greshock J., Liang S., Barchetti A., Hasegawa K., Kim S., Giannakakis A., Li C., O'Brien-Jenkins A., Katsaros D., Butzow R., Coukos G., Zhang L. Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment. PLoS One 2008, 3:e1758.
121. Zheng H., Kavanagh J.J., Hu W., Liao Q., Fu S. Hormonal therapy in ovarian cancer. Int. J. Gynecol. Cancer 2007, 17:325-338.
122. Zheng W., Lu J.J., Luo F., Hsieh J., Wang C.Y., Zhang C., Chang L., Cho M.M., Stanczyk F.Z. Tumor stroma as the main source of inhibin production in ovarian epithelial tumors. Am. J. Reprod. Immunol. 2000, 44:104-113.
123. Zheng W., Luo M.P., Welt C., Lambert-Messerlian G., Sung C.J., Zhang Z., Ying S.Y., Schneyer A.L., Lauchlan S.C., Felix J.C. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol. Oncol. 1998, 69:23-31.
124. Zhu J., Braun E.L., Kohno S., Antenos M., Xu E.Y., Cook R.W., Lin S.J., Moore B.C., Guillette L.J., Jardetzky T.S., Woodruff T.K. Phylogenomic analyses reveal the evolutionary origin of the inhibin alpha-subunit, a unique TGFbeta superfamily antagonist. PLoS One 2010, 5:e9457.